Phaseline

Companies › Meitheal Pharmaceuticals

Meitheal Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 4, 2 Phase 3; Infectious disease, Other; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fosfomycin (ZTI-01)
UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
MURAAPhase 4Healthy Lactating Women; Infections, Bacterial; Gram Negative Infections; Urinary Tract InfectionsSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06440304Fosfomycin (ZTI-01)Phase 4Infections, BacterialInfectious diseaseDec 2026
NCT07063095Fosfomycin (ZTI-01)Phase 3Gram Negative InfectionsInfectious diseaseDec 2026
NCT05709028Fosfomycin (ZTI-01)Phase 3Urinary Tract InfectionsInfectious diseaseAug 2027
NCT07618299Fosfomycin (ZTI-01)Phase 4Healthy Lactating WomenOtherSep 2027

From the company's SEC filings

Complete response letters from FDA

Targets

MURAA (1)

Companies with the same targets

–

Companies built like this

BioVersys SAS Avenue Therapeutics Freya Biosciences ApS BioAegis Therapeutics Aligos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.